Trial Profile

The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 26 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary) ; Baricitinib (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Tofacitinib (Primary) ; Upadacitinib (Primary)
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms SYBRA

Most Recent Events

06 Oct 2025 Planned End Date changed from 1 Apr 2024 to 1 Mar 2023.
06 Oct 2025 Planned primary completion date changed from 1 Oct 2023 to 1 Mar 2023.
13 Mar 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com